Instructions Sulfocamphocaine-Darnitsa solution for injection 100 mg/ml ampoule 2 ml No. 10
Composition
active ingredients: DL-sulfocamphoric acid, novocaine;
1 ml of solution contains: DL-sulfocamphoric acid 49.6 mg, novocaine base 50.4 mg;
excipient: water for injections.
Dosage form
Solution for injection.
Main physicochemical properties: clear colorless or slightly yellowish liquid.
Pharmacotherapeutic group
Cardiological drugs. ATX code C01E B.
Pharmacological properties
Pharmacodynamics
Sulfocamphocaine-Darnitsa belongs to the group of analeptic drugs. The mechanism of action of the drug is due to the excitation of the central nervous system, primarily the centers of the medulla oblongata both directly and through the carotid sinus. The drug tones the respiratory and vasomotor centers, enhances metabolic processes in the heart muscle, increasing its sensitivity to the influence of sympathetic nerves. Sulfocamphocaine-Darnitsa affects the vessels - blood redistribution occurs, the vessels of the abdominal organs narrow, the tone of the venous vessels increases, the blood flow to the heart increases slightly, coronary blood flow, blood supply to the brain and lungs improves. The cardiotonic effect is associated with an adrenosensitizing effect, increased respiration and glycolysis processes associated with the phosphorylation of macroergic compounds.
Pharmacokinetics
Sulfocamphocaine-Darnitsa is rapidly absorbed after subcutaneous, intramuscular, intravenous administration. In the body, during metabolism, it undergoes oxidation and conjugation with glucuronic acid. Metabolites are excreted mainly by the kidneys, while urine has a medicinal odor. Partially excreted with exhaled air, through the respiratory tract and with bile.
Indication
Acute and chronic respiratory failure; acute heart failure in geriatrics; respiratory depression in pneumonia and other infectious diseases; cardiogenic and anaphylactic shock; alcohol poisoning, mild forms of poisoning with sleeping pills.
Contraindication
Hypersensitivity to camphor, novocaine or other components of the drug; epilepsy, tendency to convulsions.
Interaction with other medicinal products and other types of interactions
When using Sulfocamphocaine-Darnitsa simultaneously with other medications, it is possible:
with drugs that depress the central nervous system – weakening of the effects of the latter;
with anticholinesterase agents – weakening of the action of the latter;
with suxamethonium – prolongation of neuromuscular blockade caused by suxamethonium;
with MAO inhibitors – increased risk of arterial hypertension;
with cardiac glycosides, diuretics, analgesics, steroid hormones - increased analeptic effect of sulfocamphocaine.
The drug may sometimes be prescribed to reduce side effects during chemotherapy with 5-fluorouracil.
It is not recommended to drink alcohol while using the medicine.
Application features
Use with caution in patients with arterial hypotension (hypotensive effect of novocaine).
Use during pregnancy or breastfeeding
There is no objective information in evidence-based medicine about the use of Sulfocamphocaine-Darnitsa during pregnancy, therefore, the drug should not be used by pregnant women. The possibility of Sulfocamphocaine-Darnitsa passing into milk during breastfeeding cannot be ruled out, therefore, when using it, breastfeeding should be discontinued.
Ability to influence reaction speed when driving vehicles or other mechanisms
During treatment, caution should be exercised when driving vehicles and working with complex mechanisms, and in case of dizziness, refrain from potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.
Method of administration and doses
Sulfocamphocaine-Darnitsa is administered subcutaneously, intramuscularly or intravenously (slowly, jet or drip) to adults in a single dose of 2 ml. For dilution, 0.9% sodium chloride solution should be used. If necessary, the drug can be used 2-3 times a day. The maximum daily dose for adults is 12 ml.
In acute cases, the drug should be administered intravenously.
In chronic respiratory failure and heart failure, use intramuscularly or subcutaneously. The course of treatment can be 20-30 days.
Children
The medicine should not be used in children.
Overdose
Symptoms: headache, dizziness; in acute poisoning - facial redness, pathological motor activity, delirium, epileptiform convulsions.
Treatment: antipsychotic and anticonvulsant drugs. For mild psychomotor agitation, tranquilizers or sedatives.
Adverse reactions
Gastrointestinal: dyspeptic disorders.
Cardiovascular system: decrease or increase in blood pressure, palpitations, chest pain.
From the blood and lymphatic system: methemoglobinemia.
On the part of the immune system: hypersensitivity reactions, including angioedema, anaphylactic shock, skin rashes, itching, hyperemia, urticaria.
General disorders and administration site conditions: hyperemia, rash, and itching at the injection site.
Others: fever, involuntary urination.
Expiration date
3 years.
Storage conditions
Store out of the reach of children in the original packaging at a temperature not exceeding 25 ° C. Do not freeze.
Packaging
2 ml in an ampoule; 5 ampoules in a contour blister pack; 2 contour blister packs in a pack.
Vacation category
According to the recipe.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and its business address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
